Back to Prescriptions

Biosimilars: What They Are

Biosimilars: What They Are
Prescription Medicines Editorial 5 May 2026

Biological medicines are large, complex molecules produced in living cells rather than synthesised chemically - antibodies, hormones, and the injectable treatments used in rheumatoid arthritis, inflammatory bowel disease, psoriasis and cancer. Because living systems cannot produce an exactly identical copy, a follow-on version is called a biosimilar rather than a generic: highly similar, with no clinically meaningful differences, but not molecularly identical. That distinction is why they are prescribed and recorded by brand and batch.

How they differ from generics

A generic tablet contains the same active molecule as the original - chemically identical, made to the same specification. Demonstrating equivalence is largely a matter of showing the drug reaches the bloodstream at the same rate and extent.

A biological molecule is orders of magnitude larger and its structure depends on the cell line and manufacturing process. Two batches of even the original product differ slightly from each other. So a biosimilar is assessed against a much broader package: structural analysis, laboratory comparison, and clinical studies showing equivalent effectiveness and safety.

The regulatory bar is high. A biosimilar is not an approximation waved through on cost grounds - it is a separately licensed product that has had to demonstrate it behaves the same way.

Why you may have been switched

Biosimilars cost substantially less than originator biologics, and the savings are large enough to fund treating more people. NHS services have moved patients onto them at scale.

Switching is normally a planned, supported process rather than something that happens at the pharmacy counter, because these are specialist medicines. You should be told in advance, given information, and shown the device if it differs.

Evidence from switching programmes has generally shown outcomes are maintained. If you were switched and things have been fine, that is the expected result.

The device often changes too

This is the practical difference people notice most. The pen or syringe may look and work differently - a different grip, a different needle cover, a different sound when it fires, sometimes a different injection volume or a citrate-free formulation that stings less.

Ask for a demonstration and for the manufacturer's training materials. Getting the technique right matters more than the molecular question, and injection technique is where problems actually arise.

Sharps disposal is unchanged - see our guide to needles and sharps disposal.

Batch numbers and reporting

Because these products are not identical, traceability matters. Keep a note of the brand name and batch number of what you are given, and include both when reporting any suspected side effect.

Many are under additional monitoring and carry a black triangle, meaning all suspected side effects should be reported however minor - our guides to black triangle medicines and how Yellow Card works cover why.

Our guide to why some medicines are prescribed by brand covers the wider group of medicines where the specific product matters rather than just the active ingredient.

The nocebo effect

Studies of biosimilar switching have consistently found higher rates of reported side effects and discontinuation when patients are anxious about the change or poorly informed about it - an effect attributed largely to expectation rather than to the product.

That is not a reason to dismiss anyone's experience. It is a reason for the switch to be explained properly rather than announced, and a reason to raise concerns before rather than after.

If you feel worse after a switch, report it. It should be investigated on its merits, and switching back is possible where there is a clinical reason.

What has not changed

The monitoring, the infection risk and the precautions are the same as with the originator. Blood tests continue on the same schedule, the alert card still applies, and live vaccines are still generally avoided - our guide to infection risk on immune-suppressing medicines covers this.

Storage requirements are usually the same too, typically refrigerated - see where to keep your medicines, and check the rules if you are travelling.

Interchangeability and pharmacy substitution

Unlike generics, a pharmacist cannot substitute one biosimilar for another, or for the originator, at the counter. These are prescribed by brand, and a change is a prescribing decision made by your specialist team.

If the product you are given differs from what you expected, query it before leaving. Our guides to why your tablets look different and Serious Shortage Protocols cover where substitution is and is not permitted.

Questions worth asking

  • Is this a biosimilar, and which brand am I now on?
  • Is the device different, and can someone show me?
  • What should I do if I think it is not working as well?
  • Where do I find the batch number?
  • Does anything about my monitoring change?

Related reading: How Medicines Get Their Names, with more on prescriptions and pharmacy services in Prescriptions.